("
Director/ PDMR Shareholding
Non-Executive Director's Share Transfer
The Company has been notified of the following transactions in relation to
The Company was notified on
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
|
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
|
|
||||
|
b)
|
LEI
|
213800LS272L4FIDOH92 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary share of 10p each in |
||||
|
|
|
|||||
|
Identification code |
GB00BD3VFW73 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
Transfer to The
|
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
|
|
|||||
|
- Price |
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
|
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
Enquiries
Tel: +44 (7827) 036059
Email: cosec@convatec.com
Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the